This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.» Read More
Some of the most prominent names in biotechnology plunged on Thursday as the Nasdaq headed for its worst day in nearly two years.
CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.
Eli Lilly and Takeda Pharmaceutical were ordered to pay billions in damages over claims that they concealed cancer risks of its Actos diabetes drug.
Heather Bresch Mylan CEO, discusses the concern over capping drug prices and the impact of Obamacare on rising drug costs.
U.S. health advisers recommended approval of MannKind's inhaled diabetes drug, and said the treatment could help those wary of needles.
Biotech has been so hot the past two years that the sector is starting to raise red flags.
Why do some drugs, like Gilead's Sovaldi, cost more in the U.S. than in other countries. Shelia Dharmarajian reports for "Nightly Business Report."
The FTC has sued pharmaceutical companies $1 billion for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired.
Max Herrmann, partner and healthcare research analyst at Oriel Securities, said biotech stocks have gone through a correction after a "phenomenal" rally.
The U.S. government is prohibited by law from negotiating drug prices, reports CNBC's Sheila Dharmarajan.
A high-priced drug sold by Gilead Sciences is under lawmakers' scrutiny. But one analyst says there's a bigger problem.
Biogen CEO George Scangos talks about future growth opportunities at the company on CNBC's "Fast Money."
MediWound develops treatments for severe burns and hard to heal wounds. Gal Cohen, MediWound CEO, discusses his company's medical solutions and the results of its IPO.
Arkansas Supreme Court overturns $1.2 billion judgment against Johnson & Johnson over drug marketing.
Dr. Richard Saul wrote a book called "ADHD Does Not Exist." Saul is certain attention ADHD, or attention deficit hyperactivity disorder exists only in its symptoms. The condition does not exist.
CNBC's Sheila Dharmarajan reports 15 percent of high school aged children are diagnosed with ADHD, or attention deficit hyperactivity disorder.
Pfizer said a court had invalidated a key patent behind its blockbuster Celebrex drug, and plans to appeal the judgement.
A drug company worker accusing his employer of encouraging excessive dosage in heartburn medications faces a last-ditch U.S. Supreme Court bid.
Ranbaxy Laboratories issued a recall of generic versions of the cholesterol drug Lipitor in the U.S. because of potential dosage issues, WSJ reported.
Pfizer is in clinical trials to create an over-the-counter version of cholesterol drug, Lipitor. Barbara Ryan, FTI Consulting, discusses challenges the pharmaceutical will face.
Get the best of CNBC in your inbox